{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:47:43Z","timestamp":1792691263135,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.atherosclerosis.2025.120555","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:45:28Z","timestamp":1761723928000},"page":"120555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Not all fibrates are made equal: Learning from biology and clinical trials"],"prefix":"10.1016","volume":"411","author":[{"given":"Alberto","family":"Zambon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120555_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","volume":"18","author":"Fruchart","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: when should we treat it?","volume":"120","author":"Gomez-Delgado","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2025.120555_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11739-011-0669-5","article-title":"The epidemiological concept of residual risk","volume":"6","author":"Vanuzzo","year":"2011","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/157340310791162686","article-title":"Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: subgroup analysis from FIELD","volume":"6","author":"Hermans","year":"2010","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/met.2014.0049","article-title":"Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?","volume":"13","author":"Halcox","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib7","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1093\/eurheartj\/ehab531","article-title":"Keeping remnants in perspective","volume":"42","author":"Boren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib9","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib11","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MOL.0000000000000779","article-title":"The iterative lipid impact on inflammation in atherosclerosis","volume":"32","author":"Kraaijenhof","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-Containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/metabo14030169","article-title":"Effect of adding apolipoprotein B testing on the prevalence of dyslipidemia and risk of cardiovascular disease in the Korean adult population","volume":"14","author":"Choi","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib15","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2337\/dc19-0501","article-title":"Residual hypertriglyceridemia and estimated atherosclerotic cardiovascular disease risk by statin use in U.S. adults with diabetes: National health and nutrition examination survey 2007-2014","volume":"42","author":"Fan","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib16","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib17","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.15420\/ecr.2023.16","article-title":"The role of triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease","volume":"18","author":"Gabani","year":"2023","journal-title":"European cardiology"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib18","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib19","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib21","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","article-title":"Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells","volume":"94","author":"Marx","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/01.ATV.0000154140.73570.00","article-title":"Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation","volume":"25","author":"Duez","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910545","article-title":"The role of PPAR alpha in the modulation of innate immunity","volume":"22","author":"Grabacka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102696","article-title":"Peroxisome proliferator-activated receptor alpha in lipoprotein metabolism and atherosclerotic cardiovascular disease","volume":"11","author":"Fuior","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib27","doi-asserted-by":"crossref","first-page":"13470","DOI":"10.1074\/jbc.270.22.13470","article-title":"Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III","volume":"270","author":"Hertz","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPARalpha modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/14728214.11.3.379","article-title":"Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis","volume":"11","author":"Pourcet","year":"2006","journal-title":"Expet Opin Emerg Drugs"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MOL.0b013e328341a5a8","article-title":"Role of fibrates in cardiovascular disease prevention, the ACCORD-lipid perspective","volume":"22","author":"Elam","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib35","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/01.CIR.103.23.2828","article-title":"Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT)","volume":"103","author":"Bloomfield Rubins","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib36","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the committee of principal investigators","volume":"40","year":"1978","journal-title":"Br Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib38","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","article-title":"Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes","volume":"2","author":"Elam","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12933-020-01002-x","article-title":"Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study","volume":"19","author":"Zhu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib41","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib42","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2337\/dc21-1288","article-title":"Efficacy and safety of K-877 (pemafibrate), a selective PPARalpha modulator, in European patients on Statin therapy","volume":"45","author":"Ginsberg","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib43","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.25.7.1198","article-title":"Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia","volume":"25","author":"Athyros","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib44","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.amjcard.2010.11.023","article-title":"Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia","volume":"107","author":"Krysiak","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib45","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.clinthera.2021.08.005","article-title":"Efficacy and safety of fenofibrate-statin combination therapy in patients with inadequately controlled triglyceride levels despite previous statin monotherapy: a multicenter, randomized, double-blind, phase IV study","volume":"43","author":"Park","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib49","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc20-1533","article-title":"Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean national health insurance service cohort","volume":"44","author":"Jo","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib50","article-title":"Use of fenofibrate on cardiovascular outcomes in Statin users with metabolic syndrome: propensity matched cohort study","volume":"366","author":"Kim","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155327","article-title":"Fenofibrate add-on to Statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels","volume":"137","author":"Kim","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Boren","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib53","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"Jorgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib54","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehaa172","article-title":"Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: mendelian randomization in the copenhagen general population study","volume":"41","author":"Kaltoft","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib55","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurjpc\/zwad107","article-title":"Remnant cholesterol: a reliable prognostic marker?","volume":"31","author":"Pirillo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106873","article-title":"Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment","volume":"195","author":"Galimberti","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib57","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2023.02.034","article-title":"Clinical trial design for triglyceride-rich lipoprotein-lowering therapies: JACC focus seminar 3\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"Raja","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib60","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib61","first-page":"305","article-title":"American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"vol. 29","author":"Samson","year":"2023"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib63","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clinthera.2005.06.017","article-title":"Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study","volume":"27","author":"Davidson","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib64","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.clinthera.2004.10.008","article-title":"Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib65","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib66","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/VHRM.S3390","article-title":"Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing","volume":"4","author":"Farnier","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib67","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0002-9149(03)00111-5","article-title":"Effects of adding fenofibrate (200 Mg\/Day) to simvastatin (10 mg\/day) in patients with combined hyperlipidemia and metabolic syndrome","volume":"91","author":"Vega","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib68","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5551\/jat.63659","article-title":"Efficacy and safety of pemafibrate versus bezafibrate to treat patients with hypertriglyceridemia: a randomized crossover study","volume":"30","author":"Nakamura","year":"2023","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1549687","article-title":"Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study","volume":"16","author":"Takeda","year":"2025","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib70","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","article-title":"Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia","volume":"12","author":"Yamashita","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1475-2840-13-71","article-title":"Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study","volume":"13","author":"Ohno","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00005344-200001000-00022","article-title":"Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state","volume":"35","author":"Genest","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0021-9150(02)00321-0","article-title":"Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control","volume":"166","author":"Cavallero","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib74","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2337\/dc07-0015","article-title":"Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome","volume":"30","author":"Rosenson","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib75","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2337\/dc11-2556","article-title":"Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial","volume":"36","author":"Reyes-Soffer","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12933-016-0332-6","article-title":"Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial","volume":"15","author":"Arbel","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaf053","article-title":"Fenofibrate therapy and risk of heart failure outcomes in patients with type 2 diabetes: a propensity-matched cohort study","author":"Kim","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib78","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1194\/jlr.P001834","article-title":"Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study","volume":"51","author":"Wojczynski","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib79","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/dc21-1429","article-title":"Haptoglobin phenotype modifies the effect of fenofibrate on risk of coronary event: ACCORD lipid trial","volume":"45","author":"Warren","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib80","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/db19-0973","article-title":"PPARA polymorphism influences the cardiovascular benefit of fenofibrate in type 2 diabetes: findings from ACCORD-lipid","volume":"69","author":"Morieri","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib81","first-page":"6","article-title":"Effects of fibrates on lipid profile: a meta-analysis of randomized controlled trials","volume":"4","author":"Olmastroni","year":"2025","journal-title":"Eur Ath J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib82","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s11883-023-01175-2","article-title":"How to handle elevated triglycerides: life after PROMINENT","volume":"25","author":"Pirillo","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib83","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis : off J National Kidney Found"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib84","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib85","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib86","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.2174\/0929867311320260009","article-title":"Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives","volume":"20","author":"Simo","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101428","article-title":"Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: a propensity-matched cohort study","volume":"49","author":"Kim","year":"2023","journal-title":"Diabetes Metabol"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib88","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/imj.15733","article-title":"Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy","volume":"52","author":"Quinn","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.atherosclerosis.2025.120555_bib89","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of fenofibrate on progression of diabetic retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:30:48Z","timestamp":1783690248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025014534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":89,"alternative-id":["S0021915025014534"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120555","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Not all fibrates are made equal: Learning from biology and clinical trials","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120555"}}